A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
Abstract Osimertinib was a third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug Administration (FDA) in 2015 for treatment of non-small cell lung cancer (NSCLC). Our study was to explore the adverse events (AEs)...
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Nature Portfolio
2022-11-01
|
| Collection: | Scientific Reports |
| Accès en ligne: | https://doi.org/10.1038/s41598-022-23834-1 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|